- Home
- NEGG vs CDXS Comparison
NEGG vs CDXS Comparison
Compare NEGG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CDXS
- Stock Information
- Founded
- NEGG 2001
- CDXS 2002
- Country
- NEGG United States
- CDXS United States
- Employees
- NEGG N/A
- CDXS N/A
- Industry
- NEGG Other Specialty Stores
- CDXS Major Chemicals
- Sector
- NEGG Consumer Discretionary
- CDXS Industrials
- Exchange
- NEGG Nasdaq
- CDXS Nasdaq
- Market Cap
- NEGG 122.3M
- CDXS 201.3M
- IPO Year
- NEGG 2010
- CDXS 2010
- Fundamental
- Price
- NEGG $16.83
- CDXS $2.78
- Analyst Decision
- NEGG
- CDXS Buy
- Analyst Count
- NEGG 0
- CDXS 2
- Target Price
- NEGG N/A
- CDXS $11.00
- AVG Volume (30 Days)
- NEGG 1.3M
- CDXS 880.2K
- Earning Date
- NEGG 08-28-2025
- CDXS 08-07-2025
- Dividend Yield
- NEGG N/A
- CDXS N/A
- EPS Growth
- NEGG N/A
- CDXS N/A
- EPS
- NEGG N/A
- CDXS N/A
- Revenue
- NEGG $1,235,576,000.00
- CDXS $49,815,000.00
- Revenue This Year
- NEGG N/A
- CDXS $12.77
- Revenue Next Year
- NEGG N/A
- CDXS $22.12
- P/E Ratio
- NEGG N/A
- CDXS N/A
- Revenue Growth
- NEGG N/A
- CDXS N/A
- 52 Week Low
- NEGG $3.32
- CDXS $1.90
- 52 Week High
- NEGG $26.40
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- NEGG 69.10
- CDXS 64.41
- Support Level
- NEGG $15.00
- CDXS $2.32
- Resistance Level
- NEGG $17.74
- CDXS $2.58
- Average True Range (ATR)
- NEGG 2.00
- CDXS 0.17
- MACD
- NEGG 0.44
- CDXS 0.05
- Stochastic Oscillator
- NEGG 90.44
- CDXS 81.08
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.